Reuters video regarding yesterday’s hearing:
Share this:
About This Blog
Eye on FDA is published by Mark Senak of Fleishman-Hillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of Fleishman-Hillard or its clients.Posts by Date
Posts by Category
- About Me
- Advisory Committee Prepapartion
- Advocacy
- Approvable Letters
- Approval Announcements
- Biologics
- Business/Industry News
- Clinical Trials
- Comparative Effectiveness
- Complete Response Letters
- Crisis Communications
- Current Affairs
- Drug Importation
- Drug Safety
- DSHEA
- DTC Advertising
- FDA
- FDA Image
- FDA Policy
- Finance
- Food
- Generic Drugs
- Healthcare Communications and the Next Ten Years - A Series
- Industry Image
- Intellectual Property
- Legislation
- Marketing
- Medical Apps
- Medical Devices
- Mental Health
- Minorities
- Miscellaney
- New and Social Media
- News
- OTC Switches
- PDUFA
- Pharma Industry Image
- Podcast
- Politics
- Pricing and Value
- Proposed Legislation
- Regulatory Communications
- REimbursement
- Research
- Risk Management
- Safety and Clinical Trials
- Safety and Risk Issues
- Science
- Social Media
- Tutorial
- Uncategorized
- Useful Resources
- Video
- Vitamins and Supplements
- Warning Letters
- Weblogs
- Weekly Roundup
The FDA has a tough line to walk to try and get medications to people that can receive benefit, but not so early as to miss major problems. When side effects occur only in 0.1% of the subjects, you need to have 10s of thousands of subjects to really see it become statistically significant from placebo. Yes, it is sad that this happens, but there is just no way to prove that drugs are conclusively safe before they are approved.